Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL1672747

O=S(=O)(O)C(F)(F)F.O=[N+]([O-])c1ccc2[nH]cnc2c1

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.58
NAMPT P43490 1/20 0.58
XDH P47989 1/20 0.58
ALDH1A1 P00352 4/20 0.47
PARP1 P09874 1/20 0.47
TDP1 Q9NUW8 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 5/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
GAA P10253 1/20 0.40
LMNA P02545 1/20 0.40
GRIA1 P42261 2/20 0.39
GRIA2 P42262 2/20 0.39
GRIA3 P42263 2/20 0.39
GRIA4 P48058 2/20 0.39
KIF11 P52732 1/20 0.38
POLB P06746 3/20 0.38
MAOB P27338 1/20 0.38
NOS1 P29475 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL18169501 1.00 CYP3A4 (0.58) CYP3A4NAMPTXDHALDH1A1PARP1
Trifluoromethanesulfonic Acid SCHEMBL18169502 0.91 CYP3A4 (0.73) CYP3A4NAMPTXDHALDH1A1PARP1
Benzimidazole SCHEMBL28288616 0.88 CYP3A4 (0.64) CYP3A4NAMPTXDHALDH1A1PARP1
Nitric Acid SCHEMBL4907401 0.87 CYP3A4 (0.71) CYP3A4NAMPTXDHALDH1A1PARP1
SCHEMBL29923659 0.86 CYP3A4 (0.77) CYP3A4NAMPTXDHALDH1A1PARP1
SCHEMBL271340 0.86 CYP3A4 (0.77) CYP3A4NAMPTXDHALDH1A1PARP1
SCHEMBL8425555 0.84 CYP3A4 (0.75) CYP3A4NAMPTXDHALDH1A1PARP1
Silver SCHEMBL11230934 0.84 CYP3A4 (0.75) CYP3A4NAMPTXDHALDH1A1PARP1
Alcohol SCHEMBL28252889 0.81 CYP3A4 (0.65) CYP3A4NAMPTXDHALDH1A1PARP1
Acetic Acid SCHEMBL28050837 0.81 CYP3A4 (0.65) CYP3A4NAMPTXDHALDH1A1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125414-A1 PRODUCTION METHOD OF OLIGONUCLEOTIDE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2026-05-07 US disclosed
EP-4151597-B1 INORGANIC POROUS SUBSTRATE, INORGANIC POROUS SUPPORT, AND NUCLEIC ACID PRODUCTION METHOD SUMITOMO CHEMICAL CO (JP) 2026-04-15 EP disclosed
EP-4137500-B1 METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER SUMITOMO CHEMICAL CO (JP) 2026-03-11 EP disclosed
US-12540156-B2 Method for producing nucleic acid oligomer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2026-02-03 US disclosed
US-12522629-B2 Method for producing nucleic acid oligomer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2026-01-13 US disclosed
US-12509483-B2 Method for producing nucleic acid oligomers SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2025-12-30 US disclosed
US-12509485-B2 Method for producing nucleic acid oligomer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2025-12-30 US disclosed
EP-4644404-A1 OLIGONUCLEOTIDE PRODUCTION METHOD Sumitomo Chemical Company, Limited (JP) 2025-11-05 EP disclosed
US-12391716-B2 Process of preparing nucleic acid oligomer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2025-08-19 US disclosed
US-12377409-B2 Inorganic porous carrier, and production method for nucleic acid using same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2025-08-05 US disclosed
US-10253153-B2 Linker and support for solid phase synthesis of nucleic acid, and production method of nucleic acid using said support NITTO DENKO CORPORATION (JP) 2019-04-09 US disclosed
WO-2018019748-A1 5'S-LNA NUCLEOTIDES AND OLIGONUCLEOTIDES F. HOFFMANN-LA ROCHE AG (CH) 2018-02-01 WO disclosed
US-20160311847-A1 LINKER AND SUPPORT FOR SOLID PHASE SYNTHESIS OF NUCLEIC ACID, AND PRODUCTION METHOD OF NUCLEIC ACID USING SAID SUPPORT NITTO DENKO CORPORATION (JP) 2016-10-27 US disclosed
EP-2620444-B1 Linker and support for solid phase synthesis of nucleic acid NITTO DENKO CORP (JP) 2015-05-06 EP disclosed
US-8835656-B2 Linker and support for solid phase synthesis of nucleic acid NITTO DENKO CORPORATION (JP) 2014-09-16 US disclosed
US-8669356-B2 Linker and support for solid phase synthesis of nucleic acid NITTO DENKO CORPORATION (JP) 2014-03-11 US disclosed
US-20130197117-A1 LINKER AND SUPPORT FOR SOLID PHASE SYNTHESIS OF NUCLEIC ACID NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2013-08-01 US disclosed
EP-2620444-A1 Linker and Support for Solid Phase Synthesis of Nucleic Acid Nitto Denko Corporation (JP) 2013-07-31 EP disclosed
EP-2357188-A1 Linker and support for solid phase synthesis of nucleic acid Nitto Denko Corporation (JP) 2011-08-17 EP disclosed
US-20110092690-A1 LINKER AND SUPPORT FOR SOLID PHASE SYNTHESIS OF NUCLEIC ACID NITTO DENKO CORPORATION (JP) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125414-A1 PRODUCTION METHOD OF OLIGONUCLEOTIDE NSUN2, DDX41, FBL CYP3A4 1329/4885NAMPT 4362/4885XDH 374/4885
US-12391716-B2 Process of preparing nucleic acid oligomer POLRMT, RNGTT, POLM CYP3A4 2209/4885NAMPT 462/4885XDH 2629/4885
US-12509483-B2 Method for producing nucleic acid oligomers POLM, RNGTT, POLRMT CYP3A4 3968/4885NAMPT 3530/4885XDH 2199/4885
US-10253153-B2 Linker and support for solid phase synthesis of nucleic acid, and production method of nucleic acid using said support RNGTT, NSUN2, NSUN3 CYP3A4 3694/4885NAMPT 970/4885XDH 1609/4885
US-12509485-B2 Method for producing nucleic acid oligomer RNGTT, POLM, NSUN2 CYP3A4 3869/4885NAMPT 3681/4885XDH 1528/4885
US-20160311847-A1 LINKER AND SUPPORT FOR SOLID PHASE SYNTHESIS OF NUCLEIC ACID, AND PRODUCTION METHOD OF NUCLEIC ACID USING SAID SUPPORT RNGTT, NSUN2, NSUN3 CYP3A4 3694/4885NAMPT 970/4885XDH 1609/4885
US-12540156-B2 Method for producing nucleic acid oligomer NSUN2, RNGTT, RNMT CYP3A4 4846/4885NAMPT 3281/4885XDH 1849/4885
US-20110092690-A1 LINKER AND SUPPORT FOR SOLID PHASE SYNTHESIS OF NUCLEIC ACID RNGTT, NSUN2, SSU72 CYP3A4 4224/4885NAMPT 919/4885XDH 2008/4885
US-12377409-B2 Inorganic porous carrier, and production method for nucleic acid using same SLCO2A1, SLCO2B1, SLCO1A2 CYP3A4 3692/4885NAMPT 3949/4885XDH 3061/4885
US-20130197117-A1 LINKER AND SUPPORT FOR SOLID PHASE SYNTHESIS OF NUCLEIC ACID SSU72, NSUN2, RNGTT CYP3A4 3603/4885NAMPT 1554/4885XDH 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.